SOURCE-LINKED STUDY SUMMARY
Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a).
Abstract summarizedQuality not appraised
- What was studied
- Two studies examined anabolic-steroid exposure and blood lipids: an unblinded comparison of self-selected users and nonusers, and a randomized, double-blind nandrolone-versus-placebo trial.
- Who / model studied
- The observational study included 19 steroid users and 16 nonusers, all healthy male strength athletes. The randomized trial involved 16 bodybuilders.
- Studied dose & schedule
- Users self-administered steroids for eight or 14 weeks. The trial tested intramuscular nandrolone decanoate, 200 mg/week for eight weeks, against placebo.
- What the study found
- Self-selected steroid use was associated with HDL falling from 1.08 to 0.43 mmol/l and Apo-B rising from 0.96 to 1.32 g/l. Several changes persisted six weeks after stopping. Total cholesterol and triglycerides were unchanged. Nandrolone did not change HDL or Apo-B; lipoprotein(a) declined in both trial groups and returned to baseline after withdrawal.
- Limitations & context
- The effect of nandrolone-related lipoprotein(a) changes on atherosclerosis remains unestablished. Lipid-marker changes alone do not demonstrate cardiovascular benefit.
Read summary source ↗ · Prepared 9/24/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1136/bjsm.2003.000199